Acceleron Aerospace

Acceleron Aerospace company information, Employees & Contact Information

Acceleron Aerospace is a dynamic startup focused on revolutionizing the field of space exploration and education. Our mission is to inspire and educate students of all ages, foster groundbreaking research, and develop cutting-edge space propulsion technologies for ambitious interplanetary missions. With our comprehensive range of services and partnerships with esteemed institutions, we aim to propel the future of space exploration.
Looking for a particular Acceleron Aerospace employee's phone or email?

Acceleron Aerospace Questions

News

Are Nuclear Propulsion Systems the Future of Space Exploration? - Universe Today

Are Nuclear Propulsion Systems the Future of Space Exploration? Universe Today

Tag: acceleron fusion - American Nuclear Society

Tag: acceleron fusion American Nuclear Society

Acceleron advances cold fusion technology - Nuclear Engineering International

Acceleron advances cold fusion technology Nuclear Engineering International

Acceleron Fusion Secures $24M Series A Led by Lowercarbon Capital and Collaborative Fund to Revolutionize Clean Energy with Muon-Catalyzed Fusion - PRWeb

Acceleron Fusion Secures $24M Series A Led by Lowercarbon Capital and Collaborative Fund to Revolutionize Clean Energy with Muon-Catalyzed Fusion PRWeb

Acceleron Announces Partnership With Fiserv to Deliver Seamless Foreign Exchange Services - Newswire.com

Acceleron Announces Partnership With Fiserv to Deliver Seamless Foreign Exchange Services Newswire.com

Merck’s Acceleron Integration To Take Out 143 Jobs in Cambridge, MA - BioSpace

Merck’s Acceleron Integration To Take Out 143 Jobs in Cambridge, MA BioSpace

Oracle Introduces New Cloud Networking Capabilities for Any Workload - Oracle

Oracle Introduces New Cloud Networking Capabilities for Any Workload Oracle

Merck's reported $11B Acceleron buy could help it diversify beyond Keytruda, but antitrust hurdles loom: analysts - Fierce Pharma

Merck's reported $11B Acceleron buy could help it diversify beyond Keytruda, but antitrust hurdles loom: analysts Fierce Pharma

Exclusive: Acceleron Fusion has raised $15M to take a stab at colder fusion, filing reveals - TechCrunch

Exclusive: Acceleron Fusion has raised $15M to take a stab at colder fusion, filing reveals TechCrunch

Acceleron provides biggest biopharma deal this year, with $11.5B sale to Merck - BioPharma Dive

Acceleron provides biggest biopharma deal this year, with $11.5B sale to Merck BioPharma Dive

Merck picks up Acceleron for $11.5B - drugdiscoverytrends.com

Merck picks up Acceleron for $11.5B drugdiscoverytrends.com

Merck agrees to acquire Acceleron Pharma for $11.5bn - Pharmaceutical Technology

Merck agrees to acquire Acceleron Pharma for $11.5bn Pharmaceutical Technology

Merck to buy Acceleron for about $11.5 bln in rare disease drug push - Reuters

Merck to buy Acceleron for about $11.5 bln in rare disease drug push Reuters

Report: Merck Strikes with $11 Billion Deal for Acceleron and Phase III PAH Drug - BioSpace

Report: Merck Strikes with $11 Billion Deal for Acceleron and Phase III PAH Drug BioSpace

It's a wrap: Merck collects enough Acceleron shares for $11.5B buyout despite activist investor defiance - Fierce Pharma

It's a wrap: Merck collects enough Acceleron shares for $11.5B buyout despite activist investor defiance Fierce Pharma

Acceleron and Braid Partner to Bring International Payment Automation to Community Financial Institutions and Drive Non-Interest Income - Newswire.com

Acceleron and Braid Partner to Bring International Payment Automation to Community Financial Institutions and Drive Non-Interest Income Newswire.com

Acceleron soars on blood pressure data despite lengthy road to market - BioPharma Dive

Acceleron soars on blood pressure data despite lengthy road to market BioPharma Dive

UPDATED: Merck cuts 143 jobs at Acceleron right on heels of $11.5B buyout - Fierce Pharma

UPDATED: Merck cuts 143 jobs at Acceleron right on heels of $11.5B buyout Fierce Pharma

Report: Multiple Suitors - Including BMS - Vied for Acceleron’s Attention - BioSpace

Report: Multiple Suitors - Including BMS - Vied for Acceleron’s Attention BioSpace

Novartis May Have a Suitor for Sandoz; Merck Closes Acceleron Deal - BioSpace

Novartis May Have a Suitor for Sandoz; Merck Closes Acceleron Deal BioSpace

Merck to Buy Acceleron Pharma for $11.5 Billion - WSJ - The Wall Street Journal

Merck to Buy Acceleron Pharma for $11.5 Billion - WSJ The Wall Street Journal

Acceleron pulmonary hypertension drug succeeds in mid-stage clinical trial - statnews.com

Acceleron pulmonary hypertension drug succeeds in mid-stage clinical trial statnews.com

Merck will acquire Acceleron Pharma for $11.5 billion - Chemical & Engineering News

Merck will acquire Acceleron Pharma for $11.5 billion Chemical & Engineering News

Merck completes $11B Acceleron Pharma acquisition - NJBIZ

Merck completes $11B Acceleron Pharma acquisition NJBIZ

Merck started its Acceleron pursuit at $160 per share, but CEO Davis balked at paying more than $180 - Fierce Pharma

Merck started its Acceleron pursuit at $160 per share, but CEO Davis balked at paying more than $180 Fierce Pharma

Bristol Myers Squibb engaged in Acceleron buyout talks but couldn't justify the price: report - Fierce Pharma

Bristol Myers Squibb engaged in Acceleron buyout talks but couldn't justify the price: report Fierce Pharma

Acceleron Corp Becomes a Digital Correspondent Bank - Newswire.com

Acceleron Corp Becomes a Digital Correspondent Bank Newswire.com

Acceleron dealt pipeline setback - BioPharma Dive

Acceleron dealt pipeline setback BioPharma Dive

Acceleron Abandons Charcot-Marie-Tooth Program After Trial Failure - BioSpace

Acceleron Abandons Charcot-Marie-Tooth Program After Trial Failure BioSpace

Yet another Acceleron investor challenges Merck's $11.5B acquisition offer: Bloomberg - Fierce Pharma

Yet another Acceleron investor challenges Merck's $11.5B acquisition offer: Bloomberg Fierce Pharma

Acceleron Stops Clinical Development of ACE-083 as Treatment for FSHD - Muscular Dystrophy News

Acceleron Stops Clinical Development of ACE-083 as Treatment for FSHD Muscular Dystrophy News

Bristol Myers, Acceleron's Reblozyl moves closer to blockbusterland with new blood disorders nod - Fierce Pharma

Bristol Myers, Acceleron's Reblozyl moves closer to blockbusterland with new blood disorders nod Fierce Pharma

Robert Zeldin to take post at Acceleron as its CMO retires - Fierce Biotech

Robert Zeldin to take post at Acceleron as its CMO retires Fierce Biotech

Acceleron's PAH drug sotatercept hits the mark in phase 2 - Fierce Biotech

Acceleron's PAH drug sotatercept hits the mark in phase 2 Fierce Biotech

Merck nails phase 3 sotatercept win, making good on its $11.5B Acceleron buy - Fierce Biotech

Merck nails phase 3 sotatercept win, making good on its $11.5B Acceleron buy Fierce Biotech

Acceleron blood disease drug hits goal in pivotal clinical trial - statnews.com

Acceleron blood disease drug hits goal in pivotal clinical trial statnews.com

More activist pressure for Merck's $11.5B Acceleron deal as another hedge fund balks—but BMS appears ready to deal - Fierce Pharma

More activist pressure for Merck's $11.5B Acceleron deal as another hedge fund balks—but BMS appears ready to deal Fierce Pharma

Merck refiles $11.5B Acceleron deal with the FTC. But extending regulators' review time only one benefit - Fierce Pharma

Merck refiles $11.5B Acceleron deal with the FTC. But extending regulators' review time only one benefit Fierce Pharma

Avoro Capital Releases Presentation Detailing Why Acceleron Shareholders Should Not Tender Into Merck’s Inadequate Offer - Business Wire

Avoro Capital Releases Presentation Detailing Why Acceleron Shareholders Should Not Tender Into Merck’s Inadequate Offer Business Wire

Four firms shape Merck’s $11.5 bln bet on drugmaker Acceleron - Reuters

Four firms shape Merck’s $11.5 bln bet on drugmaker Acceleron Reuters

Merck to buy Acceleron for about $11.5 billion in rare-disease drugs push - CNBC

Merck to buy Acceleron for about $11.5 billion in rare-disease drugs push CNBC

Seido Acceleron gravel wheelset review £950.00 - off.road.cc

Seido Acceleron gravel wheelset review £950.00 off.road.cc

Acceleron to Develop Sotatercept in PAH - drugdiscoverytrends.com

Acceleron to Develop Sotatercept in PAH drugdiscoverytrends.com

Merck to acquire Acceleron in a deal worth around $11.5bn - PMLiVE

Merck to acquire Acceleron in a deal worth around $11.5bn PMLiVE

Post-acquisition, Merck to lay off 170 Acceleron employees - The Business Journals

Post-acquisition, Merck to lay off 170 Acceleron employees The Business Journals

Acceleron Stock Is Skyrocketing After Surprise Success for Heart Drug - Barron's

Acceleron Stock Is Skyrocketing After Surprise Success for Heart Drug Barron's

Acceleron Announces Sotatercept Achieved Primary and Secondary Endpoints in the PULSAR Phase 2 Placebo-Controlled Trial in Patients with Pulmonary Arterial Hypertension - Business Wire

Acceleron Announces Sotatercept Achieved Primary and Secondary Endpoints in the PULSAR Phase 2 Placebo-Controlled Trial in Patients with Pulmonary Arterial Hypertension Business Wire

Merck to buy Cambridge rare-disease specialist Acceleron for $11.5 billion - The Boston Globe

Merck to buy Cambridge rare-disease specialist Acceleron for $11.5 billion The Boston Globe

Oracle expands Acceleron networking platform - Tech Observer Magazine

Oracle expands Acceleron networking platform Tech Observer Magazine

J. Calnan & Assoc. celebrates grand opening of Acceleron Pharma's cGMP manufacturing facility - NEREJ

J. Calnan & Assoc. celebrates grand opening of Acceleron Pharma's cGMP manufacturing facility NEREJ

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant